Top Page
Zai Lab Ltd
(Frankfurt:9688)
Zai Lab Ltd (9688) vs. iShares MSCI Hong Kong ETF (EWH)
Zai Lab Ltd Business Overview & Revenue Model
Zai Lab Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 427.80M | 398.99M | 266.72M | 215.04M | 144.31M | 48.96M |
| Gross Profit | 266.92M | 251.13M | 170.90M | 141.02M | 92.07M | 32.22M |
| EBITDA | -195.33M | -242.99M | -365.11M | -384.66M | -689.46M | -262.96M |
| Net Income | -212.52M | -257.10M | -334.62M | -481.99M | -692.44M | -298.16M |
Balance Sheet | ||||||
| Total Assets | 1.16B | 1.19B | 1.04B | 1.22B | 1.61B | 1.30B |
| Cash, Cash Equivalents and Short-Term Investments | 732.16M | 779.67M | 806.45M | 1.01B | 1.41B | 1.19B |
| Total Debt | 191.40M | 153.47M | 15.15M | 20.39M | 15.54M | 18.60M |
| Total Liabilities | 372.37M | 344.86M | 240.18M | 174.54M | 230.00M | 128.29M |
| Stockholders Equity | 791.74M | 840.90M | 796.12M | 1.05B | 1.38B | 1.17B |
Cash Flow | ||||||
| Free Cash Flow | -230.99M | -276.39M | -206.67M | -392.63M | -568.18M | -226.72M |
| Operating Cash Flow | -175.31M | -214.87M | -198.18M | -367.64M | -549.23M | -216.06M |
| Investing Cash Flow | -54.43M | -375.19M | -10.78M | 420.02M | 249.96M | -554.83M |
| Financing Cash Flow | 332.01M | 349.89M | -6.43M | -1.73M | 820.20M | 1.13B |
Zai Lab Ltd Technical Analysis
Zai Lab Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$48.21B | 52.45 | 27.37% | ― | 2.57% | 18.79% | |
61 Neutral | HK$10.51B | 40.39 | 13.34% | ― | 206.58% | ― | |
57 Neutral | HK$14.98B | ― | -21.42% | ― | 240.05% | -140.09% | |
54 Neutral | HK$48.98B | ― | -16.25% | ― | 44.21% | 46.11% | |
51 Neutral | $7.93B | -0.32 | -43.43% | 2.21% | 22.30% | -1.88% | |
47 Neutral | HK$55.77B | ― | -45.12% | ― | 47.62% | 28.72% | |
42 Neutral | €28.24B | ― | -29.51% | ― | 32.07% | 33.55% |
Zai Lab Ltd Corporate Events
Zai Lab Limited announced its unaudited financial results for the second quarter of 2025, reporting a 9% year-over-year increase in total revenues to $110 million. The company highlighted significant progress in its product pipeline, including record patient utilization of VYVGART and promising data for ZL-1310 in SCLC and bemarituzumab in gastric cancer. With a 28% reduction in operating loss and expectations of achieving profitability by the fourth quarter, Zai Lab is poised for growth with multiple high-impact product launches and a robust pipeline.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Limited announced the filing of its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, with the U.S. Securities and Exchange Commission. This regulatory filing is significant for stakeholders as it provides detailed insights into the company’s financial performance and operational status, which can impact its market positioning and investor confidence.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Limited has announced that its Audit Committee will review and approve the unaudited interim results for the first half of 2025 on August 7, 2025. The results, prepared in accordance with U.S. GAAP and SEC rules, will be published on the same day. Following the announcement, the company will host a live earnings teleconference and webcast to discuss the results. This announcement signifies Zai Lab’s commitment to transparency and adherence to regulatory standards, potentially impacting its market position and stakeholder confidence.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Ltd has announced the grant of share options, restricted share units, and performance share units under its 2024 Equity Incentive Plan. This move, which includes significant allocations to key personnel such as Dr. Samantha Du, aims to align the interests of employees with the company’s growth objectives and maintain competitive compensation practices. The grants are structured without performance targets or clawback mechanisms, reflecting the company’s customary practices and market competitiveness.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Limited has announced a change in its head office and principal place of business in the People’s Republic of China. Effective July 1, 2025, the company’s new location will be in Pudong, Shanghai. This move may indicate strategic positioning within the region, potentially impacting its operational efficiency and market presence in China.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Limited announced the resignation of Ms. Nelly Au-Yeung as joint company secretary and authorized representative, effective June 27, 2025. Mr. Frazor Titus Edmondson III will assume the role of sole company secretary and authorized representative, ensuring continuity in corporate governance. The board expressed gratitude to Ms. Au-Yeung for her contributions.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Ltd announced the granting of share options and restricted share units under its 2024 Equity Incentive Plan. On June 3, 2025, the company granted options to subscribe for 2,500 American Depositary Shares (ADSs) to one employee and restricted share units covering 4,104 ADSs to three employees. This move is part of Zai Lab’s strategy to align employee incentives with company performance, although the grants do not include performance targets or clawback mechanisms. The compensation committee believes this approach is market competitive and consistent with the company’s customary practices.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
Zai Lab Ltd announced the grant of 9,800 Restricted Share Units to two employees under its 2024 Equity Incentive Plan. This initiative aims to recognize and reward the employees’ contributions and incentivize their continued efforts towards the company’s success. The grants, which have no performance targets or clawback mechanisms, are seen as market competitive and aligned with the company’s practices, potentially enhancing employee retention and motivation.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.